Rui Ge, Cong Xun, Jingzhou Yang, Weitao Jia, Yuancheng Li
{"title":"In vivo therapeutic effect of wollastonite and hydroxyapatite on bone defect","authors":"Rui Ge, Cong Xun, Jingzhou Yang, Weitao Jia, Yuancheng Li","doi":"10.1088/1748-605X/ab4238","DOIUrl":null,"url":null,"abstract":"The treatment of large-area bone defects is a huge challenge and the current research hot spot is to prepare composite materials to promote the new bone formation. In this study, the rat skull defect was repaired by implanting pure wollastonite and hydroxyapatite composites, which proved that it has a good effect on the treatment of bone defects. 60 SD rats were used as research objects. The animals were randomly divided into wollastonite group, wollastonite-hydroxyapatite composite group and hydroxyapatite group. The three groups of bone scaffolds were filled into the rats’ skull defects. At 6 and 12 weeks after surgery, we conducted Micro-CT analysis, HE staining, Masson trichrome staining, Alizarin red staining and Microfil analysis, to assess the therapeutic and regeneration effects of three groups. At 6 weeks after implantation, the morphology results showed that little newly formed bone was observed in wollastonite group, on the contrary, more new bone in the surgical defects formed in the wollastonite-hydroxyapatite composite group and hydroxyapatite group. At 12 weeks after surgery, histology analyses revealed that the regenerated bone became more mature in each groups. The morphology showed that the maturity of new bone was improved and the scaffold material was partially absorbed in wollastonite-hydroxyapatite composite group. CT scan observation showed that on the coronal plane, the defect repair area of wollastonite-hydroxyapatite composite group was integrated with the surrounding normal bone tissue, and the sacffold material was tightly integrated with the defect edge. The results of Microfil showed that compared with wollastonite group and hydroxyapatite group, wollastonite-hydroxyapatite composite group formed more blood vessels after 12 weeks of surgery. The wollastonite-hydroxyapatite composite biomaterial can promote the formation and growth of new bone in the defect area, and it is considered safe.","PeriodicalId":9016,"journal":{"name":"Biomedical materials","volume":" ","pages":""},"PeriodicalIF":3.9000,"publicationDate":"2019-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1088/1748-605X/ab4238","citationCount":"17","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomedical materials","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.1088/1748-605X/ab4238","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENGINEERING, BIOMEDICAL","Score":null,"Total":0}
引用次数: 17
Abstract
The treatment of large-area bone defects is a huge challenge and the current research hot spot is to prepare composite materials to promote the new bone formation. In this study, the rat skull defect was repaired by implanting pure wollastonite and hydroxyapatite composites, which proved that it has a good effect on the treatment of bone defects. 60 SD rats were used as research objects. The animals were randomly divided into wollastonite group, wollastonite-hydroxyapatite composite group and hydroxyapatite group. The three groups of bone scaffolds were filled into the rats’ skull defects. At 6 and 12 weeks after surgery, we conducted Micro-CT analysis, HE staining, Masson trichrome staining, Alizarin red staining and Microfil analysis, to assess the therapeutic and regeneration effects of three groups. At 6 weeks after implantation, the morphology results showed that little newly formed bone was observed in wollastonite group, on the contrary, more new bone in the surgical defects formed in the wollastonite-hydroxyapatite composite group and hydroxyapatite group. At 12 weeks after surgery, histology analyses revealed that the regenerated bone became more mature in each groups. The morphology showed that the maturity of new bone was improved and the scaffold material was partially absorbed in wollastonite-hydroxyapatite composite group. CT scan observation showed that on the coronal plane, the defect repair area of wollastonite-hydroxyapatite composite group was integrated with the surrounding normal bone tissue, and the sacffold material was tightly integrated with the defect edge. The results of Microfil showed that compared with wollastonite group and hydroxyapatite group, wollastonite-hydroxyapatite composite group formed more blood vessels after 12 weeks of surgery. The wollastonite-hydroxyapatite composite biomaterial can promote the formation and growth of new bone in the defect area, and it is considered safe.
期刊介绍:
The goal of the journal is to publish original research findings and critical reviews that contribute to our knowledge about the composition, properties, and performance of materials for all applications relevant to human healthcare.
Typical areas of interest include (but are not limited to):
-Synthesis/characterization of biomedical materials-
Nature-inspired synthesis/biomineralization of biomedical materials-
In vitro/in vivo performance of biomedical materials-
Biofabrication technologies/applications: 3D bioprinting, bioink development, bioassembly & biopatterning-
Microfluidic systems (including disease models): fabrication, testing & translational applications-
Tissue engineering/regenerative medicine-
Interaction of molecules/cells with materials-
Effects of biomaterials on stem cell behaviour-
Growth factors/genes/cells incorporated into biomedical materials-
Biophysical cues/biocompatibility pathways in biomedical materials performance-
Clinical applications of biomedical materials for cell therapies in disease (cancer etc)-
Nanomedicine, nanotoxicology and nanopathology-
Pharmacokinetic considerations in drug delivery systems-
Risks of contrast media in imaging systems-
Biosafety aspects of gene delivery agents-
Preclinical and clinical performance of implantable biomedical materials-
Translational and regulatory matters